During the last session, Lyra Therapeutics Inc (NASDAQ:LYRA)’s traded shares were 3.33 million, with the beta value of the company hitting 0.05. At the end of the trading day, the stock’s price was $0.09, reflecting an intraday loss of -10.10% or -$0.01. The 52-week high for the LYRA share is $0.42, that puts it down -366.67 from that peak though still a striking 11.11% gain since the share price plummeted to a 52-week low of $0.08. The company’s market capitalization is $6.26M, and the average trade volume was 1.83 million shares over the past three months.
Lyra Therapeutics Inc (LYRA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. LYRA has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.1.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Lyra Therapeutics Inc (LYRA) registered a -10.10% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -10.10% in intraday trading to $0.09, hitting a weekly high. The stock’s 5-day price performance is -15.34%, and it has moved by -3.18% in 30 days. Based on these gigs, the overall price performance for the year is -81.90%.
The consensus price target of analysts on Wall Street is $0.5, which implies an increase of 82.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $0.5 and $0.5 respectively. As a result, LYRA is trading at a discount of -455.56% off the target high and -455.56% off the low.
Lyra Therapeutics Inc (LYRA) estimates and forecasts
In the rating firms’ projections, revenue will decrease -43.92% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 161.33k as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 162.67k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 598k and 195k respectively. In this case, analysts expect current quarter sales to shrink by -73.02% and then drop by -16.58% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -2.22%. While earnings are projected to return 55.94% in 2025, the next five years will return 21.95% per annum.
LYRA Dividends
Lyra Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 4.77 million shares, is of CITADEL ADVISORS LLC’s that is approximately 7.2912% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.32 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lyra Therapeutics Inc (LYRA) shares are iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Mar 31, 2025 indicates that iShares Trust-iShares Russell 2000 ETF owns about 2.37 shares. This amounts to just over 3.59 percent of the company’s overall shares, with a $0.22 million market value. The same data shows that the other fund manager holds slightly less at 992.54, or about 1.51% of the stock, which is worth about $93696.0.
